Radiation Oncology Group
EORTC 228544 – A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma.
EORTC demonstrated that providing patients with ‘low’-dose (45 Gy) radiotherapy, was equally good as the ‘high’-dose (59.4 Gy) radiotherapy provided. This meant that the ‘low’-dose not only improved tumor control but also reduced toxicity to low-grade glioma patients. This study contributed to determining the standard radiotherapy dose.